Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How To Have A Winning R&D Strategy In Trying Times: An Interview With Merck Research Labs’ Gary Herman

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck's 'fail fast' attitude toward R&D not only "more than pays for itself," it's "going to open up opportunities for us to do a lot more with our investment," Herman said.

You may also be interested in...



Translational Research Faces Cultural, Not Just Scientific, Barriers To Success; Industry, Academia, Govt. Meet At NIH To Talk Collaboration

NIH's translational research consortium may have to transcend fundamental "cultural differences" that have dogged industry/academia collaborations for decades in order to usher in the new era of public/private collaboration envisioned when the Clinical and Translational Sciences Awards program was created four years ago

Translational Research Faces Cultural, Not Just Scientific, Barriers To Success; Industry, Academia, Govt. Meet At NIH To Talk Collaboration

NIH's translational research consortium may have to transcend fundamental "cultural differences" that have dogged industry/academia collaborations for decades in order to usher in the new era of public/private collaboration envisioned when the Clinical and Translational Sciences Awards program was created four years ago

Back To School: Catch Up On Our Executive Interviews

Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.

Related Content

Topics

UsernamePublicRestriction

Register

PS069606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel